Back to Search
JONATHAN LUSTGARTEN, M.D.
M.D.
Neurological Surgery Physician
NPI: 1255472940IndividualAccepts Medicare
Specialties, Licenses & Credentials
Neurological Surgery PhysicianPrimary
Neurological Surgery
Code: 207T00000X
25MA06243100(NJ)199245(NY)
CMS Specialties
PrimaryNEUROSURGERY
Education
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Class of 1988
Research & Publications (20)
Cancer, aging and immunotherapy: lessons learned from animal models.
PMID 19238382·Cancer Immunol Immunother·2009
6-review
rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
PMID 19115932·Viral Immunol·2008
8-other
Using a novel resource to decrease proteomic biomarker identification time.
PMID 18999243·AMIA Annu Symp Proc·2008
8-other
Improving classification performance with discretization on biomedical datasets.
PMID 18999186·AMIA Annu Symp Proc·2008
8-other
Successful devascularization of carotid body tumors by covered stent placement in the external carotid artery.
PMID 18971039·J Vasc Surg·2008
5-case
Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
PMID 18794141·Cancer Res·2008
7-preclinical
Implications of aging and self-tolerance on the generation of immune and antitumor immune responses.
PMID 18593945·Cancer Res·2008
4-observational
EPO-KB: a searchable knowledge base of biomarker to protein links.
PMID 18400772·Bioinformatics·2008
8-other
CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.
PMID 17828396·Cancer Immunol Immunother·2008
7-preclinical
High accumulation of T regulatory cells prevents the activation of immune responses in aged animals.
PMID 17142731·J Immunol·2006
7-preclinical
Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing.
PMID 17015692·J Immunol·2006
8-other
Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope.
PMID 16424210·J Immunol·2006
7-preclinical
Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB.
PMID 16289924·Exp Gerontol·2006
7-preclinical
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
PMID 15856473·Int J Cancer·2005
7-preclinical
Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
PMID 15797254·Microvasc Res·2005
7-preclinical
Aged mice develop protective antitumor immune responses with appropriate costimulation.
PMID 15383582·J Immunol·2004
4-observational
Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.
PMID 15102791·Infect Immun·2004
7-preclinical
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.
PMID 14991605·Eur J Immunol·2004
4-observational
Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice.
PMID 14522915·Cancer Res·2003
7-preclinical
Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
PMID 12827309·Cancer Immunol Immunother·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 121 STATE ROUTE 36, SUITE 330
WEST LONG BRANCH, NJ 07764 - Phone
- (732) 222-8866
Quick Facts
- NPI
- 1255472940
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile